About Enhancer
| Enhancer ID: | E_01_0086 |
| Species: | human |
| Position : | chr15:88633030-88635030   |
| Biosample name: | |
| Experiment class : | High+Lowthroughput |
| Enhancer type: | Enhancer |
| Disease: | Hepatitis b |
| Pubmed ID: | 31951295 |
| Enhancer experiment: | Immunohistochemistry, luciferase analysis, transfection, Southern blot, Northern blot, Western blot, RT-PCR, chromatin immunoprecipitation analysis, microarray data analysis |
| Enhancer experiment description: | Our findings suggest that ISG20 exerts the anti-HBV activity by acting as a putative repressor binding to the HBV EnhII/Cp region. |
About Target gene
| Target gene : | ISG20 |
| Strong evidence: | qRT-PCR,qPCR,ChIP,3C |
| Less strong evidence: | RNA-Seq |
| Target gene experiment description: | Our findings suggest that ISG20 exerts the anti-HBV activity by acting as a putative repressor binding to the HBV EnhII/Cp region. |
About TF
| TF name : | -- |
| TF experiment: | ???????????????Southern blot ?Northern blot?Western blot?RT-PCR ?????????????????? |
| TF experiment description: | Our findings suggest that ISG20 exerts the anti-HBV activity by acting as a putative repressor binding to the HBV EnhII/Cp region. |
About Function
| Enhancer function : | Our findings suggest that ISG20 exerts the anti-HBV activity by acting as a putative repressor binding to the HBV EnhII/Cp region. |
| Enhancer function experiment: | Immunohistochemical staining |
| Enhancer function experiment description: |
Our findings suggest that ISG20 exerts the anti-HBV activity by acting as a putative repressor binding to the HBV EnhII/Cp region. |
About SNP
| SNP ID: | -- |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|
Enhancer associated network
The number on yellow line represents the distance between enhancer and
target gene